meRfi®-GM
Cenicriviroc & Non-alcoholic Steatohepatitis (NASH)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Cenicriviroc has shown anti-fibrotic activity in murine models of Non-Alcoholic Steatohepatitis (NASH / MASH) and has been evaluated in clinical trials on patients with Non-alcoholic Steatohepatitis (NASH)
Cenicriviroc prevented and reversed hepatic steatosis, insulin resistance, inflammation, and fibrogenesis in the livers of Non-Alcoholic Steatohepatitis (NASH / MASH) mice via M2 [macrophage polarization](brain://sVZvN__SKkKK_FVBzg035g/M…
References (Sources)
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
- Cenicriviroc suppresses and reverses steatohepatitis by regulating macrophage infiltration and M2 polarization in mice